Immunotherapy for colorectal cancer

Patrick M. Boland, Wen Wee Ma

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.

Original languageEnglish (US)
Article number50
JournalCancers
Volume9
Issue number5
DOIs
StatePublished - May 11 2017

Fingerprint

Immunotherapy
Colorectal Neoplasms
DNA Mismatch Repair
Clinical Trials
Research
Pharmaceutical Preparations
Population
Therapeutics
Turcot syndrome

Keywords

  • Anti-PD1
  • Colon cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunotherapy for colorectal cancer. / Boland, Patrick M.; Ma, Wen Wee.

In: Cancers, Vol. 9, No. 5, 50, 11.05.2017.

Research output: Contribution to journalReview article

Boland, Patrick M. ; Ma, Wen Wee. / Immunotherapy for colorectal cancer. In: Cancers. 2017 ; Vol. 9, No. 5.
@article{11917ff5c4c0441dad0ea04edc10903a,
title = "Immunotherapy for colorectal cancer",
abstract = "The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.",
keywords = "Anti-PD1, Colon cancer, Immunotherapy",
author = "Boland, {Patrick M.} and Ma, {Wen Wee}",
year = "2017",
month = "5",
day = "11",
doi = "10.3390/cancers9050050",
language = "English (US)",
volume = "9",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Immunotherapy for colorectal cancer

AU - Boland, Patrick M.

AU - Ma, Wen Wee

PY - 2017/5/11

Y1 - 2017/5/11

N2 - The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.

AB - The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic population. Current research focuses on advancing immunotherapy to earlier stages of the disease including adjuvant and first-line metastatic settings, and on inducing sensitivity to immune checkpoint inhibitor therapy through a combinatorial approach. Here, we review the contemporary understanding of the immune and molecular landscape in colorectal cancer and discuss ongoing clinical trials evaluating novel combination regimens based on immune checkpoint inhibitors.

KW - Anti-PD1

KW - Colon cancer

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85019257096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019257096&partnerID=8YFLogxK

U2 - 10.3390/cancers9050050

DO - 10.3390/cancers9050050

M3 - Review article

AN - SCOPUS:85019257096

VL - 9

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 5

M1 - 50

ER -